The favorable outcomes observed with SGLT2 inhibitors in diabetic nephropathy have prompted investigation into their potential benefits in various organ systems—including the kidneys, heart, and liver—even beyond populations with diabetes [27,28,29,30,31]. This evidence concerns the gene SLC5A2 and diabetes mellitus.